Drugs / Reveratinib
last change Jan 2026 re-read 2 minutes ago

Reveratinib

Developed for
gastrointestinal stromal tumor

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
NCT05751733 Comparator Feb 2023 → Jan 2026 overdue gastrointestinal stromal tumor Xiangya Hospital of Central South University Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Reveratinib ClinicalTrials.gov intervention name — accepted as the source's own label NCT05751733